TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James…


Previous articlePsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications
Next articlePsilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders